Targeting the gastrointestinal (GI) tract with AAV is a significant challenge due to the rapid turnover of the intestinal epithelium (cells are replaced every 3–5 days), the thick protective mucus layer, and the presence of digestive enzymes and harsh pH levels.

Quick Legend: Administration Routes

• Systemic (IV): Injection into the bloodstream. Often results in poor intestinal uptake due to high liver sequestration.
• Intraluminal (Oral/Enema): Delivery directly into the gut “tube.” Faces the barrier of gastric acid, mucus, and the “washout” effect of peristalsis.
• Local (Subserosal): Direct injection into the intestinal wall during surgery. Highly efficient but clinically invasive.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV9	Enteric Neurons, Smooth Muscle	IV	The Neuro-Muscular Specialist. • The most effective natural serotype for reaching the Enteric Nervous System (ENS) via systemic injection. • Transduces the myenteric plexus but poorly targets the epithelium from the blood side.
AAV6	Intestinal Epithelium	Intraluminal	The Epithelial Performer. • Shown to have a higher affinity for the apical (luminal) surface of intestinal cells compared to AAV2 or AAV8. • Still requires “muco-active” agents to bypass the mucus layer.
AAV8	Lamina Propria, Myofibroblasts	Systemic	Generally poor at reaching the epithelium, but can transduce deeper mesenchymal cells in the intestinal wall if high titers are used.
AAV2	Epithelium (Limited)	Intraluminal	Historically used, but significantly hindered by heparin-binding, which causes it to get stuck in the mucus and glycocalyx.

---

2. Engineered & Synthetic Capsids

Engineered capsids for the gut focus on resisting degradation and improving penetration through the mucus.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV-PHP.S	Enteric Neurons (ENS)	IV	Superior ENS Targeting. • A variant of AAV9 engineered for the peripheral nervous system. • Shows significantly higher efficiency in transducing neurons across the entire length of the GI tract compared to wild-type AAV9.
AAV-DJ	Intestinal Epithelium	Intraluminal	High Infectivity. • A synthetic hybrid that exhibits very high transduction rates in intestinal organoids and in vivo when delivered locally, though susceptible to the “washout” effect.
AAV-iHLS1	Intestinal Epithelium	Oral / IV	Intestine-Homing. • A newer engineered capsid designed to bypass the liver and home specifically to the small intestine and colon.

---

3. Tropism by Target Layer

If you are targeting a specific layer of the gut, start here:

• Enteric Nervous System (ENS): AAV-PHP.S or AAV9 (via IV).
• Intestinal Epithelium (Enterocytes): AAV6 (via Intraluminal) or AAV-iHLS1.
• Intestinal Muscle (Motility Issues): AAV9 (via IV or Subserosal).
• Peyer’s Patches (Immune System): AAV1 or AAV5 have shown some utility in targeting gut-associated lymphoid tissue.

---

Critical Factor: The Turnover Barrier

The biggest obstacle in intestinal gene therapy is not just the capsid, but the clock:

1. Transient Expression: If you transduce a mature enterocyte, the gene expression will be lost in ~4 days when the cell sloughs off into the lumen.
2. The Solution: To achieve long-term expression, the AAV must reach the Intestinal Stem Cells located at the base of the Crypts of Lieberkühn. This usually requires an engineered capsid that can penetrate deep into the crypts or systemic delivery that can cross the basement membrane.